PT-141 is a high-purity peptide offered in a 10mg lyophilized powder format, intended strictly for laboratory research and development purposes. Manufactured to exceed 99% purity and tested using both HPLC and LC-MS protocols, this peptide is supplied in a sterile, sealed vial to ensure stability and integrity.
Recent research & studies
- Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.
Bremelanotide (BRM) is a cyclic peptide therapeutic whose intrinsic stability and degradation behavior have not been extensively investigated. This study aimed to develop a stability-indicating RP-HPLC method for BRM and characterize its degradation products using LC-HRMS/MS combined with computational approaches.…
- The Synthetic Melanocortin Agonist NDP-MSH Ameliorates THSD7A-Associated Membranous Nephropathy in an Active Immunization Mouse Model.
Melanocortin-based therapies have demonstrated protective effects in experimental membranous nephropathy (MN). However, existing evidence is derived exclusively from passive immunization models that lack direct involvement of human MN-associated autoimmunity, limiting translational relevance. A clinically relevant model is essential to more…
- Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.
The recent clinical success of macrocyclic peptides, such as bremelanotide and setmelanotide, highlights the potential of this modality as a "Goldilocks" chemical class, effectively balancing the properties of small molecules and biologics while optimizing their affinity, stability, and pharmacokinetics. Despite…
- Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo.
- Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
The primary objectives of this clinical trial performed with Vyleesi (Bremelanotide Injection) are: * to evaluate if Bremelanotide (BMT) is secreted in breast milk of lactating women treated with a single dose of BMT 1.75 mg SC. * to measure…
- Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.
Background: Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition affecting adult women and is associated with significant impairments in quality of life and interpersonal relationships. Despite increasing recognition of female sexual health as a clinical priority, pharmacological…
These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.
